Location of Repository

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

By Farnier Michel, Dong Qian, Shah Arvind, Johnson-Levonas Amy O and Brudi Philippe


<p>Abstract</p> <p>Background</p> <p>Fibrates have been reported to cause paradoxical decreases in HDL-C in certain patients.</p> <p>Design and methods</p> <p>This post-hoc analysis explored the frequency/magnitude of HDL-C reductions in a pooled database of mixed dyslipidemic patients (LDL-C:3.4-5.7 mmol/L;TG:1.7-5.7 mmol/L) receiving placebo (PBO), fenofibrate (FENO), ezetimibe plus FENO (EZE+FENO), or EZE/simvastatin plus FENO (EZE/SIMVA+FENO) for 12 weeks.</p> <p>Results</p> <p>PBO-treated patients had the highest incidence of HDL-C reductions from baseline (45%) compared with patients taking FENO (14%), EZE+FENO (9%), or EZE/SIMVA+FENO (9%). Reductions <30% reflected natural variability since the largest reduction in HDL-C approached 30% in the PBO group. Only 3 patients exhibited HDL-C reductions ≥30% (i.e., 2 patients in the FENO group and 1 in the EZE+FENO group). There were no differences in demographic/biochemical characteristics between patients with and without HDL-C reductions.</p> <p>Conclusions</p> <p>The incidence of paradoxical HDL-C reductions was low in mixed dyslipidemic patients receiving FENO alone or combined with EZE or EZE/SIMVA.</p> <p>Trial registrations</p> <p>Clinicaltrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00092560">NCT00092560</a> and <a href="http://www.clinicaltrials.gov/ct2/show/NCT00092573">NCT00092573</a></p

Topics: high-density lipoprotein cholesterol, fibrates, dyslipidemia, ezetimibe, simvastatin, Physiology, QP1-981, Science, Q, DOAJ:Physiology, DOAJ:Biology, DOAJ:Biology and Life Sciences, Nutritional diseases. Deficiency diseases, RC620-627
Publisher: BioMed Central
Year: 2011
DOI identifier: 10.1186/1476-511X-10-212
OAI identifier: oai:doaj.org/article:0e10509b83a0409d81ca283af9fd1aa5
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.clinicaltrials.gov/... (external link)
  • http://www.clinicaltrials.gov/... (external link)
  • https://doaj.org/toc/1476-511X (external link)
  • http://www.lipidworld.com/cont... (external link)
  • https://doaj.org/article/0e105... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.